J 2012

Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database

POPRACH, Alexandr, Zbyněk BORTLÍČEK, Tomáš BÜCHLER, Bohuslav MELICHAR, Radek LAKOMÝ et. al.

Basic information

Original name

Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database

Authors

POPRACH, Alexandr (203 Czech Republic), Zbyněk BORTLÍČEK (203 Czech Republic, belonging to the institution), Tomáš BÜCHLER (703 Slovakia), Bohuslav MELICHAR (203 Czech Republic), Radek LAKOMÝ (203 Czech Republic), Rostislav VYZULA (203 Czech Republic, guarantor), Petr BRABEC (203 Czech Republic, belonging to the institution), Marek SVOBODA (203 Czech Republic), Ladislav DUŠEK (203 Czech Republic, belonging to the institution) and Jakub GREGOR (203 Czech Republic, belonging to the institution)

Edition

Medical Oncology, 2012, 1357-0560

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.147

RIV identification code

RIV/00216224:14110/12:00062394

Organization unit

Faculty of Medicine

DOI

UT WoS

000311513800045

Keywords in English

kidney cancer; renal carcinoma; epidemiology; incidence
Změněno: 23/4/2013 00:18, Ing. Mgr. Věra Pospíšilíková

Abstract

V originále

The incidence and mortality of renal cell carcinoma (RCC) in the Czech Republic are among the highest in the world. Several targeted agents have been recently approved for the treatment of advanced/metastatic RCC. Objective: Presentation of a national clinical database for monitoring and assessment of patients with advanced/metastatic RCC treated with targeted therapy. The RenIS (RENal Information System, http://renis.registry.cz) registry is a noninterventional post-registration database of epidemiological and clinical data of patients with RCC treated with targeted therapies in the Czech Republic. Twenty cancer centres eligible for targeted therapy administration participate in the project. As of November 2011, six agents were approved and reimbursed from public health insurance, including bevacizumab, everolimus, pazopanib, sorafenib, sunitinib, and temsirolimus. As of 10 October 2011, 1,541 patients with valid recordswere entered into the database.Comparison with population-based data from the Czech National Cancer Registry revealed that RCC patients treated with targeted therapy are significantly younger (median age at diagnosis 59 vs. 66 years). Most RenIS registry patients were treated with sorafenib and sunitinib, many patients sequentially with both agents. Over 10 % of patients were also treated with everolimus in the second or third line. Progression-free survival times achieved were comparable to phase III clinical trials. The RenIS registry has become an important tool and source of information for the management of cancer care and clinical practice, providing comprehensive data onmonitoring and assessment of RCC targeted therapy on a national level.